Jasper Therapeutics to Present at 39th Annual J.P. Morgan Virtual Healthcare Conference

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Jasper Therapeutics, Inc., a biotechnology company focused on hematopoietic cell transplant therapies, today announced that Bill Lis, Executive Chairman and Chief Executive Officer, will present at the 39^th Annual J.P. Morgan Virtual Healthcare Conference on Thursday, January 14, 2021 at 4:20 p.m. Eastern Time.

About Jasper Therapeutics

Jasper Therapeutics is a biotechnology company focused on the development of novel curative therapies based on the biology of the hematopoietic stem cell. The company’s lead compound, JSP191, is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients undergoing a hematopoietic cell transplant. This first-in-class conditioning antibody is designed to enable safer and more effective curative hematopoietic cell transplants and gene therapies. For more information, please visit us at jaspertherapeutics.com.